US2006281694A1PendingUtilityA1
Glucose levels
Est. expiryApr 2, 2016(expired)· nominal 20-yr term from priority
A61P 43/00A61K 45/06A61K 31/7048A61K 31/353A61P 29/00C07D 311/32A61K 9/4858A23K 20/111C11B 5/0035A23G 1/32A61K 9/2018A23K 50/40A61K 9/2068C07D 311/62C07H 17/06C07D 311/64A23G 3/36A61K 36/5777
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are methods and compositions for improving blood glucose levels in a subject in need thereof.
Claims
exact text as granted — not AI-modified1 . A polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 3 to 18, such that there is at least one terminal monomeric unit A, and a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond for an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety, and
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof.
2 . The compound of claim 1 wherein n is 5.
3 . The compound of claim 1 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
4 . The compound of claim 1 which is isolated from a natural source.
5 . The compound of claim 4 wherein the natural source is a Theobroma or Herrania species or inter- or intra-species specific crosses thereof.
6 . The compound of claim 1 which is substantially pure.
7 . The compound of claim 1 which is purified to apparent homogeneity.
8 . The compound of claim 1 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
9 . An antineoplastic composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 3 to 18, such that there is at least one terminal monomeric unit A, and a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
10 . The composition of claim 9 wherein n is 5 to 12.
11 . The composition of claim 9 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
12 . The composition of claim 9 wherein said polymeric compound is substantially pure.
13 . The composition of claim 9 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
14 . The composition of claim 9 wherein n is 5.
15 . A method for treating a subject in need of treatment with an antineoplastic agent comprising administering to the subject an antineoplastic composition as claimed in claim 9 .
16 . The method of claim 15 , further comprising administering at least one additional antineoplastic agent.
17 . A kit for a composition of claim 9 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
18 . A composition as claimed in claim 9 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
19 . An antioxidant composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
20 . The composition of claim 19 wherein n is 2 to 10.
21 . The composition of claim 19 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
22 . The composition of claim 19 wherein said polymeric compound is substantially pure.
23 . The composition of claim 19 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
24 . The composition of claim 19 wherein n is 2 to 12.
25 . A method for treating a subject in need of treatment with an antioxidant agent comprising administering to the subject an antioxidant composition as claimed in claim 19 .
26 . The method of claim 25 , further comprising administering at least one additional antioxidant agent.
27 . A composition as claimed in claim 19 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
28 . A kit for a composition of claim 19 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
29 . A method for preserving or protecting a desired item from oxidation comprising contacting the item with a composition as claimed in claim 19 .
30 . An antimicrobial composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
31 . The composition of claim 30 wherein n is 2 to 10.
32 . The composition of claim 30 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
33 . The composition of claim 30 wherein said polymeric compound is substantially pure.
34 . The composition of claim 30 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
35 . The composition of claim 30 wherein n is selected from the group consisting of 2, 4, 5, 6, 8 and 10.
36 . A composition as claimed in claim 30 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
37 . A method for treating a subject in need of treatment with an antimicrobial agent comprising administering to the subject an antimicrobial composition as claimed in claim 30 .
38 . The method of claim 37 , further comprising administering at least one additional antimicrobial agent.
39 . A kit for a composition of claim 30 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
40 . A cyclo-oxygenase and/or lipoxygenase modulating composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
41 . The composition of claim 40 wherein n is 2 to 10.
42 . The composition of claim 40 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
43 . The composition of claim 40 wherein said polymeric compound is substantially pure.
44 . The composition of claim 40 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
45 . The composition of claim 40 wherein n is 2 to 5.
46 . A composition as claimed in claim 40 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
47 . A method for treating a subject in need of treatment with a cyclo-oxygenase and/or lipoxygenase modulating agent comprising administering to the subject a composition as claimed in claim 40 .
48 . The method of claim 47 , further comprising administering at least one additional cyclo-oxygenase and/or lipoxygenase modulating agent.
49 . A kit for a composition of claim 40 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
50 . An NO or NO-synthase modulating composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety via an ester bond;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
51 . The composition of claim 50 wherein n is 2 to 10.
52 . The composition of claim 50 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
53 . The composition of claim 50 wherein said polymeric compound is substantially pure.
54 . The composition of claim 50 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
55 . A composition as claimed in claim 50 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
56 . A method for treating a subject in need of treatment with a NO-modulating agent comprising administering to the subject an NO or NO-synthase modulating composition as claimed in claim 50 .
57 . The method of claim 56 , further comprising administering at least one additional NO or NO-synthase modulating agent.
58 . A kit for a composition of claim 50 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
59 . A method of treating a mammal in need of treatment with an NO or NO synthase agent comprising administering to the mammal a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
60 . A method of reducing NO affected hypercholesterolemia in a mammal comprising administering to said mammal a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
61 . The method of claim 60 wherein n is 2 to 10.
62 . A method for the induction of iNOS in mammalian monocyte and/or macrophages comprising contacting said monocyte and/or macrophages with a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
63 . A method of stimulating mammalian monocyte and/or macrophage NO production comprising administering to said mammal a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
64 . The method of claim 63 wherein n is 2 to 10.
65 . An in vivo glucose-modulating composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
66 . The composition of claim 65 wherein n is 2 to 10.
67 . The composition of claim 65 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
68 . The composition of claim 65 wherein said polymeric compound is substantially pure.
69 . The composition of claim 65 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
70 . A composition as claimed in claim 65 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
71 . A method for treating a subject in need of treatment with a glucose-modulating agent comprising administering to the subject a glucose-modulating agent as claimed in claim 65 .
72 . The method of claim 71 , further comprising administering at least one additional glucose-modulating agent.
73 . A kit for a composition of claim 65 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
74 . A topoisomerase II-inhibiting composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
75 . The composition of claim 74 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
76 . The composition of claim 74 wherein said polymeric compound is substantially pure.
77 . The composition of claim 74 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamin, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
78 . A composition as claimed in claim 74 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
79 . A method for inhibiting topoisomerase II which comprises contacting topoisomerase II with a composition as claimed in claim 74 .
80 . A kit for a composition of claim 74 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
81 . A non-steroidal antiinflammatory composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of the additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of an additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety, and
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
82 . The composition of claim 81 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
83 . The composition of claim 81 wherein said polymeric compound is substantially pure.
84 . The composition of claim 81 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
85 . A composition as claimed in claim 81 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
86 . A method for treating a subject in need of treatment with a non-steroidal antiinflammatory agent comprising administering to the subject a composition as claimed in claim 81 .
87 . The method of claim 86 , further comprising administering at least one additional non-steroidal antiinflammatory agent.
88 . A kit for a composition of claim 81 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
89 . An anti-gingivitis or anti-periodontitis composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
90 . The composition of claim 89 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
91 . The composition of claim 89 wherein said polymeric compound is substantially pure.
92 . The composition of claim 89 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
93 . A composition as claimed in claim 89 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
94 . A kit for a composition of claim 89 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
95 . A method of reducing periodontal disease progression in a mammal comprising administering to said mammal with a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
96 . The method of claim 95 wherein n is 2 to 10.
97 . A method of treatment of periodontal disease comprising administering to a mammal in need of such treatment a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
98 . A platelet aggregation modulating composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
99 . The composition of claim 98 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
100 . The composition of claim 98 wherein said polymeric compound is substantially pure.
101 . The composition of claim 98 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
102 . A composition as claimed in claim 98 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
103 . A kit for a composition of claim 98 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
104 . A method of modulating platelet aggregation administering to a mammal in need of such treatment with a compound of claim 98 .
105 . An apoptosis modulating composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
106 . The composition of claim 105 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
107 . The composition of claim 105 wherein said polymeric compound is substantially pure.
108 . The composition of claim 105 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
109 . A composition as claimed in claim 105 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
110 . A kit for a composition of claim 105 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
111 . A method of modulating apoptosis comprising contacting COX-2 expressing cancer cells with a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
112 . The method of claim 111 wherein n is 5.
113 . A method of inhibiting oxidative damage to DNA comprising contacting DNA with a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
114 . The composition of claim 113 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
115 . The composition of claim 113 wherein said polymeric compound is substantially pure.
116 . The composition of claim 113 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
117 . A composition as claimed in claim 113 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
118 . A kit for a composition of claim 113 comprising the compound and the carrier or diluent separately packaged, and optionally instructions for admixture or administration.
119 . A composition for treating, preventing or reducing atherosclerosis or restenosis comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
120 . The composition of claim 119 wherein the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
121 . The composition of claim 119 wherein said polymeric compound is substantially pure.
122 . The composition of claim 119 wherein the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
123 . A composition as claimed in claim 119 wherein the composition is selected from the group consisting of a tablet, capsule, Standard of Identity chocolate and non-Standard of Identity chocolate.
124 . A method of treating, preventing or reducing atherosclerosis or restenosis in a mammal comprising administering to said mammal a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
125 . The method of claim 124 wherein n is 2 to 10.
126 . A method of inhibiting the oxidation of LDL in a mammal comprising administering to said mammal a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
127 . The method of claim 126 wherein n is 2 to 12.
128 . A method of modulating thrombosis in a mammal comprising administering to said mammal a compound of claim 1 and a suitable carrier or diluent.
129 . The method of claim 128 wherein n is 2 to 12.
130 . A method of modulating cyclooxygenase-1 (COX-1) for the treatment for inflammatory bowel disease comprising administering to a mammal in need of such treatment a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
131 . A method of inhibiting bacterial growth in a mammal comprising administering to said mammal a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
132 . The method of claim 131 wherein n is 2, 4, 5, 6, 8 and 10.
133 . A method of reducing hypertension in a mammal in need of such treatment comprising administering to said mammal a composition comprising a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety;
pharmaceutically acceptable salts, derivatives thereof, and oxidation products thereof;
and a pharmaceutically acceptable carrier or excipient.
134 . The method of claim 133 wherein n is 2 to 10.
135 . A method for treating cancer in a mammal in need of such treatment, comprising administering to the mammal in an amount sufficient to effect said treatment of at least one compound in claim 1 .
136 . The method of claim 135 wherein said cancer is prostate cancer.
137 . The method of claim 135 wherein said cancer is renal cancer.
138 . The method of claim 135 wherein said cancer is colon cancer.
139 . The method of claim 135 wherein said cancer is breast cancer.
140 . The method of claim 135 wherein the cancer is feline leukemia.
141 . The method of claim 135 wherein the cancer is cervical cancer.
142 . The method of claim 135 wherein the cancer is T-cell leukemia.
143 . A method of arresting cancer cell growth in a mammal comprising administering to said mammal a compound of claim 1 and a suitable carrier or diluent.
144 . The method of claim 143 wherein n is 5.
145 . A carrier or vehicle for a pharmaceutical comprising a cocoa extract.
146 . A substantially pure polyphenol from Theobroma or Herrania species or inter- or intra-species specific crosses thereof comprising polyphenols comprising oligomers 3 through 18.
147 . A compound of claim 1 having a structure giving an NMR spectra as set forth in FIG. 48A -D.
148 . A compound of claim 1 having a structure giving an NMR spectra as set forth in FIG. 49A -D.
149 . A method for enhancing the concentration levels and distribution of cocoa procyanidins in cocoa beans by manipulating fermentation conditions.
150 . The compound as claimed in claim 1 wherein the compound is a trimer of formula [EC-(4β→8)] 2 -EC.
151 . The compound as claimed in claim 1 wherein the compound is a tetramer of formula [EC-(4β→8)] 3 -EC.
152 . The compound as claimed in claim 1 wherein the compound is a pentamer of formula [EC-(4β→8)] 4 -EC, wherein a 3-position of the terminal monomeric unit of the pentamer is optionally derivatized with a gallate and/or β-D-glucose.
153 . The compound as claimed in claim 1 wherein the compound is a hexamer of formula [EC-(4β→8)] 5 -EC.
154 . The compound as claimed in claim 1 wherein the compound is a heptamer of formula [EC-(4β→8)] 6 -EC.
155 . The compound as claimed in claim 1 wherein the compound is an octamer of formula [EC-(4β→8)] 7 -EC.
156 . The compound as claimed in claim 1 wherein the compound is a nonamer of formula [EC-(4β→8)] 8 -EC.
157 . The compound as claimed in claim 1 wherein the compound is a decamer of formula [EC-(4β→8)] 9 -EC.
158 . The compound as claimed in claim 1 wherein the compound is an undecamer of formula [EC-(4β→8)] 10 -EC.
159 . The compound as claimed in claim 1 wherein the compound is a dodecamer of formula [EC-(4β→8)] 11 -EC.
160 . The composition as claimed in claim 9 wherein the compound is selected from the group consisting of a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, a decamer of formula [EC-(4β→8)] 9 -EC, an undecamer of formula [EC-(4β→8)] 10 -EC, and a dodecamer of formula [EC-(4β→8)] 11 -EC.
161 . The composition as claimed in claim 19 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, and a decamer of formula [EC-(4β→8)] 9 -EC.
162 . The composition as claimed in claim 30 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, and a decamer of formula [EC-(4β→8)] 9 -EC.
163 . The composition as claimed in claim 40 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4538)] 8 -EC, and a decamer of formula [EC-(4β→8)] 9 -EC.
164 . The composition as claimed in claim 50 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, and a decamer of formula [EC-(4β→8)] 9 -EC.
165 . The composition as claimed in claim 65 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, and a decamer of formula [EC-(4β→8)] 9 -EC.
166 . The composition as claimed in claim 74 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, a decamer of formula [EC-(4β→8)] 9 -EC, an undecamer of formula [EC-(4β→8)] 10 -EC, and a dodecamer of formula [EC-(4β→8)] 11 -EC.
167 . The composition as claimed in claim 81 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, a decamer of formula [EC-(4β→8)] 9 -EC, an undecamer of formula [EC-(4β→8)] 10 -EC, and a dodecamer of formula [EC-(4β→8)] 11 -EC.
168 . The composition as claimed in claim 89 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, and a decamer of formula [EC-(4β→8)] 9 -EC.
169 . The composition as claimed in claim 98 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4→β8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, a decamer of formula [EC-(4β→8)] 9 -EC, an undecamer of formula [EC-(4β→8)] 10 -EC, and a dodecamer of formula [EC-(4β→8)] 11 -EC.
170 . The composition as claimed in claim 105 wherein the compound is a pentamer of formula [EC-(4β→8)] 4 -EC.
171 . The compositition as claimed in claim 119 wherein the compound is selected from the group consisting of a dimer of formula EC-(4β→8)-EC, a trimer of formula [EC-(4β→8)] 2 -EC, a tetramer of formula [EC-(4β→8)] 3 -EC, a pentamer of formula [EC-(4β→8)] 4 -EC, a hexamer of formula [EC-(4β→8)] 5 -EC, a heptamer of formula [EC-(4β→8)] 6 -EC, an octamer of formula [EC-(4β→8)] 7 -EC, a nonamer of formula [EC-(4β→8)] 8 -EC, and a decamer of formula [EC-(4β→8)] 9 -EC.
172 . A method for the identification of at least one gene induced or repressed by a polymeric compound of the formula A n , wherein A is a monomer of the formula:
wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond for an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
the sugar is optionally substituted with a phenolic moiety, and
pharmaceutically acceptable salts, derivatives thereof, oxidation products thereof, or combinations thereof,
said method comprising contacting said at least one gene or a gene product thereof with the polymeric compound using a gene expression assay.
173 . The method as claimed in claim 172 wherein said gene expression assay is selected from the group consisting of Differential Display, sequencing of cDNA libraries, Serial Analysis of Gene Expression, and expression monitoring by hybridization to high density oligonucleotide arrays.
174 . The compound as claimed in claim 1 , wherein
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
175 . The composition as claimed in claim 9 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
176 . The composition as claimed in claim 19 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
177 . The composition as claimed in claim 30 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
178 . The composition as claimed in claim 40 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
179 . The composition as claimed in claim 50 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
180 . The composition as claimed in claim 65 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
181 . The composition as claimed in claim 74 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
182 . The composition as claimed in claim 81 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
183 . The composition as claimed in claim 89 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
184 . The composition as claimed in claim 98 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
185 . The composition as claimed in claim 105 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
186 . The composition as claimed in claim 119 , wherein the compound further comprises
adjacent monomers bind at position 4 by (4→6) or (4→8); and each of X, Y and Z is H, a sugar or an adjacent monomer, with the provisos that if X and Y are adjacent monomers, Z is H or sugar and if X and Z are adjacent monomers, Y is H or sugar, and that as to at least one of the two terminal monomers, bonding of the adjacent monomer is at position 4 and optionally, Y=Z=hydrogen.
187 . The compound as claimed in claim 1 wherein the compound is a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC.
188 . The compound as claimed in claim 1 wherein the compound is a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C.
189 . The compound as claimed in claim 1 wherein the compound is a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C.
190 . The compound as claimed in claim 1 wherein the compound is a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, wherein the 3-position of a hexamer terminal monomeric unit is optionally derivatized with a gallate or a β-D-glucose.
191 . The compound as claimed in claim 1 wherein the compound is a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, wherein the 3-position of the heptamer terminal monomeric unit is optionally derivatized with a gallate or a β-D-glucose.
192 . The compound as claimed in claim 1 wherein the compound is an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, wherein the 3-position of an octamer terminal monomeric unit is optionally derivatized with a gallate or a β-D-glucose.
193 . The compound as claimed in claim 1 wherein the compound is a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, wherein the 3-position of a nonamer terminal monomeric unit is optionally derivatized with a gallate or a β-D-glucose.
194 . The compound as claimed in claim 1 wherein the compound is a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C, wherein the 3-position of a decamer terminal monomeric unit is optionally derivatized with a gallate or a β-D-glucose.
195 . The compound as claimed in claim 1 wherein the compound is an undecamer selected from the group consisting of [EC-(4β→8)] 10 -EC, [EC-(4β→8)] 9 -EC-(4β→6)-EC, [EC-(4β→8)] 9 -EC-(4β→8)-C, and [EC-(4β→8)] 9 -EC-(4β→6)-C, wherein the 3-position of an undecamer terminal monomeric unit is optionally derivatized with a gallate or a β-D-glucose.
196 . The compound as claimed in claim 1 wherein the compound is a dodecamer selected from the group consisting of [EC-(4β→8)] 11 -EC, [EC-(4β→8)] 10 -EC-(4β→6)-EC, [EC-(4β→8)] 10 -EC-(4β→8)-C, and [EC-(4β→8)] 10 -EC-(4β→6)-C, wherein the 3-position of a dodecamer terminal monomeric unit is optionally derivatized with a gallate or a β-D-glucose.
197 . The composition as claimed in claim 9 wherein the compound is selected from the group consisting of a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→38)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C, an undecamer selected from the group consisting of [EC-(4β→8)] 10 -EC, [EC-(4β→8)] 9 -EC-(4β→6)-EC, [EC-(4β→8)] 9 -EC-(4β→8)-C, and [EC-(4β→8)] 9 -EC-(4β→6)-C, and a dodecamer selected from the group consisting of [EC-(4β→8)] 11 -EC, [EC-(4β→8)] 10 -EC-(4β→6)-EC, [EC-(4β→8)] 10 -EC-(4β→8)-C, and [EC-(4β→8)] 10 -EC-(4β→6)-C.
198 . The composition as claimed in claim 19 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β43 8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, and a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β43 6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C.
199 . The composition as claimed in claim 30 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β43 8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, and a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)]g-EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C.
200 . The composition as claimed in claim 40 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, and a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C.
201 . The composition as claimed in claim 50 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, and a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C.
202 . The composition as claimed in claim 65 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, and a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C.
203 . The composition as claimed in claim 74 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C, an undecamer selected from the group consisting of [EC-(4β→8)] 10 -EC, [EC-(4β43 8)] 9 -EC-(4β→6)-EC, [EC-(4β→8)] 9 -EC-(4β→8)-C, and [EC-(4β→8)] 9 -EC-(4β→6)-C, and a dodecamer selected from the group consisting of [EC-(4β→8)] 11 -EC, [EC-(4β→8)] 10 -EC-(4β→6)-EC, [EC-(4β→8)] 10 -EC-(4β→8)-C, and [EC-(4β→8)] 10 -EC-(4β→6)-C.
204 . The composition as claimed in claim 81 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β43 6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)]g-EC, [EC-(4β→8)] 7 -EC-(413-6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C, an undecamer selected from the group consisting of [EC-(4β→8)] 10 -EC, [EC-(4β→8)] 9 -EC-(4β→6)-EC, [EC-(4β→8)] 9 -EC-(4β→8)-C, and [EC-(4β→8)] 9 -EC-(4β→6)-C, and a dodecamer selected from the group consisting of [EC-(4β→8)] 11 -EC, [EC-(4β→8)] 10 -EC-(4β→6)-EC, [EC-(4β→8)] 10 -EC-(4β→8)-C, and [EC-(4β→8)] 10 -EC-(4β→6)-C.
205 . The composition as claimed in claim 89 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, and a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C.
206 . The composition as claimed in claim 98 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β43 8)] 8 -EC-(4β→6)-C, an undecamer selected from the group consisting of [EC-(4β→8)] 10 -EC, [EC-(4β→8)] 9 -EC-(4β→6)-EC, [EC-(4β→8)] 9 -EC-(4β→8)-C, and [EC-(4β→8)] 9 -EC-(4β→6)-C, and a dodecamer selected from the group consisting of [EC-(4β→8)] 11 -EC, [EC-(4β→8)] 10 -EC-(4β→3-6)-EC, [EC-(4β→8)] 10 -EC-(4β→8)-C, and [EC-(4β→8)] 10 -EC-(4β→6)-C.
207 . The composition as claimed in claim 105 wherein the compound is selected from the group consisting of a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β→8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C.
208 . The composition as claimed in claim 119 wherein the compound is selected from the group consisting of a trimer selected from the group consisting of [EC-(4β→8)] 2 -EC, [EC-(4β→8)] 2 -C and [EC-(4β→6)] 2 -EC, a tetramer selected from the group consisting of [EC-(4β→8)] 3 -EC, [EC-(4β→8)] 3 -C and [EC-(4β→8)] 2 -EC-(4β→6)-C, a pentamer selected from the group consisting of [EC-(4β→8)] 4 -EC, [EC-(4β→8)] 3 -EC-(4β→6)-EC, [EC-(4β→8)] 3 -EC-(4β43 8)-C and [EC-(4β→8)] 3 -EC-(4β→6)-C, a hexamer selected from the group consisting of [EC-(4β→8)] 5 -EC, [EC-(4β→8)] 4 -EC-(4β→6)-EC, [EC-(4β→8)] 4 -EC-(4β→8)-C, and [EC-(4β→8)] 4 -EC-(4β→6)-C, a heptamer selected from the group consisting of [EC-(4β→8)] 6 -EC, [EC-(4β→8)] 5 -EC-(4β→6)-EC, [EC-(4β→8)] 5 -EC-(4β→8)-C, and [EC-(4β→8)] 5 -EC-(4β→6)-C, an octamer selected from the group consisting of [EC-(4β→8)] 7 -EC, [EC-(4β→8)] 6 -EC-(4β→6)-EC, [EC-(4β→8)] 6 -EC-(4β→8)-C, and [EC-(4β→8)] 6 -EC-(4β→6)-C, a nonamer selected from the group consisting of [EC-(4β→8)] 8 -EC, [EC-(4β→8)] 7 -EC-(4β→6)-EC, [EC-(4β→8)] 7 -EC-(4β→8)-C, and [EC-(4β→8)] 7 -EC-(4β→6)-C, and a decamer selected from the group consisting of [EC-(4β→8)] 9 -EC, [EC-(4β→8)] 8 -EC-(4β→6)-EC, [EC-(4β→8)] 8 -EC-(4β→8)-C, and [EC-(4β→8)] 8 -EC-(4β→6)-C.Join the waitlist — get patent alerts
Track US2006281694A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.